Skip to main content
Premium Trial:

Request an Annual Quote

Second SARS-CoV-2 Vaccine Authorized in US

The US Food and Drug Administration granted on Friday an Emergency Use Authorization for Moderna's SARS-CoV-2 vaccine, the New York Times reports. This, it adds, is the second SARS-CoV-2 vaccine to receive authorization in the US, as one from Pfizer and BioNTech was authorized a week earlier.

Last month, Moderna announced that its mRNA-based vaccine had an efficacy of 94.5 percent and, last week, a briefing report from the FDA suggested the agency was in favor of authorizing the vaccine and an advisory panel to the FDA then voted in favor of doing so. The EUA came shortly thereafter.

"With the availability of two vaccines now for the prevention of COVID-19, the FDA has taken another crucial step in the fight against this global pandemic that is causing vast numbers of hospitalizations and deaths in the United States each day," FDA Commissioner Stephen Hahn says in a statement.

The Times adds that the authorization has spurred the distribution of 5.9 million doses of the vaccine, the delivery of which will be managed by the federal government under Operation Warp Speed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.